Comparing the current results to its competitors, Connect Biopharma Holdings Limited reported Revenue increase in the 2 quarter 2026 by 5666.67 % year on year. The sales growth was above Connect Biopharma Holdings Limited's competitors' average revenue growth of 11.95 %, achieved in the same quarter.
Connect Biopharma Holdings Limited, slower than the average decrease reported by the company's competitors of -55.9 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -55.9 %
Connect Biopharma Holdings Limited's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is characterized by rapid technological advancements and intense competition. Competitors include pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. These entities have developed or are developing products or product candidates that compete with the company's offerings. Many competitors possess greater financial resources, established market presence, and expertise in research and development, manufacturing, clinical testing, regulatory approvals, reimbursement, and marketing. Competition also exists in recruiting qualified personnel, establishing clinical trial sites, patient registration, and acquiring complementary technologies. Smaller or early-stage companies may be significant competitors, particularly through collaborations with larger companies. Mergers and acquisitions may further increase competition.
Due to outstanding performance in Overall company, revenue grew by 5666.67 % Connect Biopharma Holdings Limited improved its market share, to approximately 0 %.
November 20, 2023
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023 SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 - Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company focused on developing therapies derived from T cell-driven research to improve the lives of patients with chronic inflammatory diseases, is set to reveal the long-term data from its China pivotal trial for Rademikibart. The trial studied the efficacy and safety of this treatment for individuals with moderate-to-severe atopic dermatitis (AD). The company is poised to announce the topline results...
Publicly Traded Peers of Connect Biopharma Holdings Limited
Viatris Inc Share Performance
+3.43%
30 Days
Viatris Inc
Profile
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Sources:
Connect Biopharma Holdings Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Connect Biopharma Holdings Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
